Introduction {#Sec1}
============

We recently reported the potential role of severe hematological abnormalities as prognostic markers in hospitalized patients with influenza virus infection \[[@CR1]\]. However, the role of viral load in the clinical outcome and/or in the appearance of some severe hematological abnormalities was not evaluated.

Previous studies have hypothesized that viral load of some respiratory viruses correlate with disease severity \[[@CR2]\], but this association is not clear in the case of influenza virus infection \[[@CR3], [@CR4]\]. On the contrary, other authors have found that high influenza viral load is associated with a longer duration of hospital stay in adults with viral acute respiratory illness \[[@CR5]\]. On this basis, we decided to analyze the role of influenza viral load in the outcome of the patients included in the same cohort of our previous paper \[[@CR1]\].

The aim of the present study was to assess if there is an association between viral load measured by real-time reverse-transcriptase--polymerase chain reaction (rRT-PCR) cycle threshold (Ct) value on upper respiratory tract samples and the outcome in patients who were admitted to the hospital with a confirmed influenza virus infection.

Material and methods {#Sec2}
====================

Study population {#Sec3}
----------------

This is a retrospective observational study including all adult patients with a diagnosis of influenza virus infection hospitalized from January to May 2016 in a 1300-bed tertiary teaching hospital in Madrid, Spain. The study protocol was approved by the University Hospital "12 de Octubre" Review Board.

Microbiological methods {#Sec4}
-----------------------

A case was defined by a positive result of a rRT-PCR assay performed at the local laboratory on respiratory samples (nasopharyngeal swabs (flocked swabs in UTM™ viral transport medium, Copan, Brescia, Italy)) from adult patients with respiratory symptoms suggestive of influenza. For the molecular diagnosis, RNA was extracted from 200 μl of the specimen using NucliSENS®easyMAG instrument (bioMérieux Diagnostics, Marcy l'Etoile, France) and eluted in 50 μl. Five microliters of the elution was used to perform each RT-PCR. The modular duplex rRT-PCR for influenza A/influenza B detection (Influenza A/B r-gene™, bioMérieux) was run in the LightCycler 480 instrument (Roche) \[[@CR6]\]. This test has 45 cycles of amplification and a Ct [\>]{.ul} 40 is considered below the limit of detection of the technique according to the instructions of the manufacturer.

All samples testing positive for influenza A were sub-typed using a non-commercial rRT-PCR assay as previously described \[[@CR7]\] to detect specific regions of subtypes H1 and H3 hemagglutinin from seasonal viruses. For the detection of influenza A (H1N1) pdm09 subtype, commercially available primers and probe (RealTime ready infA/H1N1 Detection set, Roche) \[[@CR8]\] were used.

The real-time PCR cycle threshold (Ct) value represents the first PCR cycle in which the fluorescent signal for the target is greater than the minimal detection level \[[@CR9], [@CR10]\].

Study definitions {#Sec5}
-----------------

Respiratory failure was defined as the need for mechanical ventilation, either non-invasive positive pressure ventilation or invasive mechanical ventilation, including those patients who had a clinical indication for ventilatory support but for some reason were finally not ventilated.

Sepsis, septic shock, and organ dysfunction were defined according to the terms proposed recently by the Third International Consensus Definitions for Sepsis and Septic Shock \[[@CR11]\], including the SOFA score and the qSOFA score. Acute respiratory distress syndrome (ARDS) was defined according to the American-European Consensus Conference on ARDS \[[@CR12], [@CR13]\].

Poor outcome was defined as a composite endpoint in which at least one of the following criteria had to be fulfilled: (a) respiratory failure, (b) SOFA ≥ 2, or (c) death (related or not related to influenza infection).

Hematological abnormalities secondary to influenza virus infection were defined as cytopenias that were in the range of the HLH-04 updated criteria proposed by the Histiocyte Society \[[@CR14]\] for the diagnosis of hematophagocytic syndrome (HPS) (hemoglobin ≤ 9 g/dl, platelets \< 100,000/μl, neutrophils \< 1000/μl). Since lymphopenia is not included in the HLH-04 criteria, we defined it as a total count less than 1000 lymphocytes/μl.

Statistical methods {#Sec6}
-------------------

A descriptive analysis of patients was initially performed according to Ct value (viral load). Descriptive analysis was performed using means (± SD) or medians with interquartile ranges (IQR). Initially, the Ct value was categorized into three groups (low Ct, ≤ 20; intermediate Ct, \> 20--30; and high Ct, \> 30) and the Kruskal-Wallis test was used to explore differences across these groups. Later, we compared patients who had a high viral load (Ct ≤ 20) with those who did not have a high viral load (Ct \> 20). Student's *t* test for independent samples was used to compare continuous variables. The Mann-Whitney *U* test was used to compare continuous variables with a non-normal distribution, and the Fisher exact test to compare proportions. Receiver operating characteristic (ROC) curve analysis was conducted to establish the best viral load that determined the presence of the composite endpoint or respiratory failure, and corresponding sensitivity and specificity were reported. The area under the ROC curve (AUC) with 95% confidence interval (CI) was also calculated. Statistical analysis was performed with IBM SPSS Statistics for Windows, Version 19.0 (Armonk, NY: IBM Corp and SAS/STAT 10.1; SAS Institute Inc., Cary, NC).

Results and discussion {#Sec7}
======================

We included 239 hospitalized patients with confirmed influenza virus infection. The mean Ct value was 26.69 ± 5.81. Twenty-seven patients (11.29%) had a low Ct, 138 cases (57.74%) had an intermediate Ct, and 74 patients (30.96%) had a high Ct. Two hundred seven cases were positive for influenza A (86.6%), all of them by the H1N1pdm09 subtype, while the other 32 cases were positive for influenza B. First of all, we want to point out that most of the previous published information of the influence of viral load of H1N1pdm09 subtype on the prognosis of patients is prior to the introduction of this strain in the vaccine \[[@CR4], [@CR15]--[@CR17]\]. In fact, only Spencer's work \[[@CR18]\] includes patients after the modification of the vaccine, but focuses on factors associated with low Ct and not in the evolution or development of complications. Therefore, to the best of our knowledge, this is the first work that analyzes the influence of influenza A H1N1pdm09 viral load on the prognosis of patients after the inclusion of the strain in the vaccine.

Clinical characteristics {#Sec8}
------------------------

Patient's demographic and clinical characteristics, as well as management of the infection, are shown in Table [1](#Tab1){ref-type="table"}. Ninety-six patients were previously vaccinated. Viral load was higher in the unvaccinated group when compared with that of the vaccinated patients (Ct 25.17 ± 5.55 vs. 27.58 ± 4.97, *p* = 0.004). Practically all of the patients were treated with oseltamivir (96.7%) in the early phase of the infection. As our work included a very homogeneous population, it is unlikely that the presence or absence of antiviral treatment has influenced the clinical course of the disease.Table 1Baseline demographic and clinical characteristics of patients with influenza infectionCharacteristicsAll patients (*n* = 239)Ct value (viral load)*P* value^a^*P* value^b^≤ 20 (*n* = 27)\> 20--30 (*n* = 138)\> 30 (*n* = 74)Age (years)67.08 ± 16.0970.11 ± 15.9166.13 ± 16.5667.72 ± 15.290.460.21Sex (male)142 (59.7%)18 (66.7%)78 (56.9%)46 (62.2%)0.550.41Charlson comorbidity index score2 (1--4)2 (0.25--3.75)2 (1--4)2 (1--3)0.580.33Previous comorbid conditions  Active smoker48 (20.1%)5 (18.5%)29 (21%)14 (18.9%)0.910.82  Obesity43 (18%)6 (22.2%)24 (17.4%)13 (17.6%)0.830.59  Asthma15 (6.3%)1 (3.7%)10 (7.2%)4 (5.4%)0.731  COPD51 (21.3%)5 (18.5%)33 (23.9%)13 (17.6%)0.520.7  Cardiovascular disease68 (28.5%)6 (22.2%)38 (27.5%)24 (32.4%)0.560.44  Immunosuppression (including steroids)\*53 (22.2%)3 (11.1%)34 (24.6%)16 (21.6%)0.290.14  Influenza vaccination (last year)96 (40.3%)10 (37%)50 (36.5%)36 (48.6%)0.210.71Influenza A H1N1pdm09 (vs influenza B)207 (86.6%)27 (100%)125 (90.6%)55 (74.3%)**\< 0.0010.031**Duration of illness prior to confirming the infection (days)3 (2--5)3 (1--7)3 (2--4.75)3.5 (2--5)0.1140.54Clinical findings at admission  Temperature (°C)37.62 ± 1.0237.9 ± 0.937.58 ± 0.9937.60 ± 1.110.390.17  Dyspnea142 (59.4%)18 (66.7%)88 (63.8%)36 (48.6%)0.0730.41  Respiratory rate19.95 ± 7.9723.83 ± 11.6619.38 ± 7.4120.26 ± 8.290.710.45  SpO~2~ (%)91.28 ± 5.9590.92 ± 4.7291.47 ± 5.191.04 ± 5.130.590.52  Bronchospasm102 (42.7%)9 (33.3%)54 (39.1%)39 (52.7%)0.0950.29  Chest X-ray abnormal findings113 (50.2%)20 (76.9%)61 (46.9%)32 (46.4%)**0.0150.004**Treatment  Oseltamivir231 (96.7%)27 (100%)134 (97.1%)70 (94.6%)0.370.6  Empiric antibiotic therapy174 (72.8%)17 (63%)103 (74.6%)54 (73%)0.450.22  Pathogen directed antibiotic therapy17 (7.1%)3 (11.1%)9 (6.5%)5 (6.8%)0.690.41  Treatment with steroids136 (56.9%)17 (63%)76 (55.1%)43 (58.1%)0.720.32Results are expressed as mean ± standard deviation or median with interquartile range (IQR) or as absolute value (percentage). \*Immunosuppression was defined as the presence of any the following: active malignant neoplasia, autoimmune disease, solid organ transplantation, HIV infection, use of steroids or chemotherapy. Use of steroids was defined as (1) more than 20 mg/day of oral prednisone during 7 days or longer or (2) less than 20 mg/day during a minimum of 3 months. *COPD* chronic obstructive pulmonary disease. ^a^Across all Ct value groups. ^b^Between high viral load group (Ct **≤** 20) and other groups combined. Bold font means significant differences between variables

Laboratory tests {#Sec9}
----------------

Very little is known about the potential influence of viral load of influenza virus on the development of cytopenias. In fact, the scarce existing information indicates that viral load of different respiratory viruses does not influence the white blood cell count in patients with an acute respiratory illness \[[@CR5]\].

Laboratory parameters of our study are presented in Table [2](#Tab2){ref-type="table"}. The mean Ct was 26.52 ± 6.45 in the group with at least one hematological abnormality vs. 26.73 ± 6.64 in the group without cytopenias (*p* = 0.81). Regarding laboratory parameters, we found that the only cell lines that seemed to be affected by the viral load are lymphocytes. Lymphopenia was present in 59.1% of patients upon admission, reaching up to 71.7% throughout hospital stay, with significant differences between the three groups according to the Ct value (*p* = 0.006 and *p* = 0.097). The mean Ct was 26.40 ± 6.15 in the group with lymphopenia vs. 27.49 ± 4.86 in the group without lymphopenia (*p* = 0.15). However, the ROC curve analysis did not show a Ct cut-off that adequately predicted the presence of lymphopenia (AUC, 0.55; 0.47--0.63, *p* = 0.19).Table 2Laboratory parameters of patients with influenza infectionCharacteristicsAll patients (*n* = 239)Ct value (viral load)*P* value^a^*P* value^b^≤ 20 (*n* = 27)\> 20--30 (*n* = 138)\> 30 (*n* = 74)Baseline laboratory findings  Leukocytes (×10^3^ cells/μl)8.1 (5.55--10.95)8.2 (5.55--11.2)8.1 (5.55--10.9)8.2 (5.55--11.2)0.860.63  Neutrophils (×10^3^ cells/μl)6.1 (3.85--9.15)6.2 (3.3--9.8)6 (3.7--9.15)6.3 (4.15--9)0.930.79  Neutrophils (%)76.71 ± 13.6982.61 ± 9.975.82 ± 13.2476.42 ± 15.6**0.0440.024**  Lymphocytes (cells/μl)800 (500--1200)500 (400--800)900 (600--1300)700 (450--1200)**0.0250.0001**  Lymphocytes (%)11 (6.02--18)7.8 (4.3--16)11.8 (6.32--20.45)11 (5.5--16.8)0.110.071  Platelets (×10^3^/μl)187 (146--245)159 (118--269)204 (155--246.5)183 (133--231)0.280.48  Hemoglobin (g/dl)13.06 ± 2.1313.41 ± 1.4112.92 ± 2.3313.22 ± 2.020.510.52  LDH (U/l)274.5 (223.7--347.7)324 (223.7--392)278 (227--364)261 (221--319)0.150.23  Hypertransaminasemia48 (20.1%)7 (25.9%)35 (25.4%)6 (8.1%)**0.008**0.42  C-reactive protein (mg/dl)5.31 (2.44--11.55)7.49 (3.72--11.87)5.36 (2.45--11.94)4.61 (2.13--9.95)0.250.15Peak laboratory values  LDH (U/l)292 (247.5--394.5)329 (248--537)296 (253--386)276 (240--366)0.250.15  LDH \> 225^¶^196 (83.8%)22 (81.5%)114 (85.1%)60 (82.2%)0.810.78  AST (mg/dl)30 (23--51)51 (22--79)30 (23.75--44.2)27 (22--44)0.290.064  C-reactive protein (mg/dl)8 (4--15)10 (4.75--13.5)8 (4--15.5)8 (3--15)0.770.34Nadir blood cell count  Leukocytes (×10^3^ cells/μl)5.8 (4.15--8.1)5.7 (3.9--8.5)5.8 (4.12--7.7)6.35 (4.27--8.45)0.730.9  Neutrophils (×10^3^ cells/μl)3.7 (2.4--5.65)3.9 (2.2--6.2)3.4 (2.4--5.27)4.45 (2.8--6.32)0.610.8  Neutrophils (%)64.09 ± 16.3968.5 ± 15.2362.14 ± 16.4766.07 ± 16.290.130.14  Lymphocytes (cells/μl)700 (400--1000)500 (300--700)700 (500--1000)600 (400--1100)0.09**0.032**  Lymphocytes (%)9.4 (5.1--16.5)7.15 (4.07--16)10.2 (5.6--16.3)9.2 (4.75--16.8)0.270.13  Platelets (×10^3^/μl)176 (119--227.5)134 (99--235)178 (135.5--228)172 (109--221.2)0.30.24  Hemoglobin (g/dl)11.96 ± 2.3511.89 ± 2.0611.92 ± 2.5412.08 ± 2.110.940.85Hematological abnormalities  \< 1000 neutrophils/μl\*14 (5.9%)2 (7.4%)7 (5.1%)5 (6.8%)0.820.66  \< 100,000 platelets/μl\*36 (15.1%)7 (25.9%)16 (11.6%)13 (17.6%)0.120.14  Hemoglobin \< 9 g/dl\*25 (10.5%)3 (11.1%)17 (12.3%)5 (6.8%)0.451  \< 1000 lymphocytes/μl170 (71.7%)24 (88.9%)93 (68.4%)53 (71.6%)0.097**0.035**Results are expressed as mean ± standard deviation or median with interquartile range (IQR) or as absolute value (percentage). *NA* not available. ^¶^Upper limit of LDH in the local laboratory is 225 mg/dl. \*According to the HLH-04 criteria. ^a^Across all Ct value groups. ^b^Between high viral load group (Ct ≤ 20) and other groups combined. Bold font means significant differences between variables

Clinical outcome {#Sec10}
----------------

As shown in Table [3](#Tab3){ref-type="table"}, we observed that pulmonary radiological findings are more frequently found in patients with higher viral loads as previously described by other authors \[[@CR17], [@CR19], [@CR20]\]. Twenty-eight patients (11.7%) developed pneumonia in the course of admission (*p* = 0.45 between groups). Eight patients with pneumonia were vaccinated (28.5%) vs. 41.7% in the group without pneumonia (*p* = 0.29).Table 3Outcome of patients with influenza infection according viral loadCharacteristicsAll patients (*n* = 239)Ct value (viral load)*P* value^a^*P* value^b^≤ 20 (*n* = 27)\> 20--30 (*n* = 138)\> 30 (*n* = 74)Length of hospital stay (days)7 (5--12)9 (6--13)7 (5--11)8 (5--12.25)0.190.34ICU admission13 (5.4%)2 (7.4%)5 (3.6%)6 (8.1%)0.340.64Pneumonia28 (11.7%)5 (18.5%)16 (11.6%)7 (9.5%)0.450.33Respiratory failure19 (7.9%)3 (11.1%)9 (6.5%)7 (9.5%)0.610.45ARDS3 (1.3%)0 (0%)1 (0.7%)2 (2.7%)0.381Invasive mechanical ventilation9 (3.8%)2 (7.4%)2 (1.4%)5 (6.8%)0.080.27Non-invasive mechanical ventilation8 (3.3%)1 (3.7%)4 (2.9%)3 (4.1%)0.91Duration of invasive mechanical ventilation (days)15.5 (8--28.5)22.5 (15--30)8 (4--18)16 (10--19)0.430.4Vasoactive drugs10 (4.2%)2 (7.4%)4 (2.9%)4 (5.4%)0.460.31Septic shock13 (5.4%)3 (11.1%)4 (2.9%)6 (8.1%)0.100.17SOFA score at ICU admission1 (0--3.75)3 (1.5--7.5)0 (0--3)2 (0.5--3.5)0.440.49SOFA ≥ 230 (15.1%)4 (19%)18 (15.7%)8 (12.7%)0.750.53qSOFA score0 (0--1)0 (0--1)0 (0--1)0 (0--1)0.190.98qSOFA ≥ 158 (39.5%)5 (35.7%)29 (34.9%)24 (48%)0.310.76Overall in-hospital mortality12 (5.2%)2 (7.7%)6 (4.5%)4 (5.5%)0.790.63Related mortality10 (4.3%)2 (7.7%)5 (3.8%)3 (4.1%)0.660.31Poor outcome (composite endpoint)42 (21.4%)5 (25%)26 (22.8%)11 (17.7%)0.670.77Results are expressed as mean ± standard deviation or median with interquartile range (IQR) or as absolute value (percentage). *ICU* intensive care unit, *ARDS* acute respiratory distress syndrome. ^a^Across all Ct value groups. ^b^Between high viral load group (Ct ≤ 20) and other groups combined

Respiratory failure was present in 7.9% of patients. We observed a slightly higher percentage of this item in those with the higher viral load without reaching statistical significance.

Poor outcome was present in 21.4% of patients with no differences between groups according to the Ct value (*p* = 0.67). The mean Ct was 26.58 ± 6.06 in the group with poor outcome vs. 26.81 ± 5.81 in the good prognosis group (*p* = 0.82). We also analyzed the association between the viral load and the need for ICU admission, without finding significant differences between groups. To the extent of our knowledge, a high viral load has not been previously analyzed as a predisposing factor for septic shock, use of vasoactive drugs, or SOFA score ≥ 2. We did not find differences in these regards, although we observed a trend to a more frequent presence of each of these items in patients with higher viral loads, as well as with mortality and the composite endpoint. We analyzed with ROC curves if the viral load had any influence on the development of ventilatory failure or the composite endpoint, without finding statistically significant relationships (Fig. [1](#Fig1){ref-type="fig"}). Overall in-hospital mortality was 5.2% and influenza-related mortality was 4.6%, without differences between groups (*p* = 0.63).Fig. 1Respiratory failure and poor outcome according to Ct value. **a** Receiver operator characteristic (ROC) curve analysis using the value of Ct for discriminating respiratory failure (AUC = 0.53; 0.38--0.69, *p* = 0.59). **b** ROC curve analysis using the value of Ct for discriminating poor outcome (defined as a composite endpoint in which at least one of the following criteria had to be fulfilled: (a) respiratory failure, (b) SOFA ≥ 2, or (c) death (related or not related to influenza infection) (AUC = 0.51; 0.41--0.61, *p* = 0.82)

As shown in Table [4](#Tab4){ref-type="table"}, there were no significant differences in the length of hospitalization according to viral load. Likewise, we did observe a slightly longer duration of admission in the subgroup of patients with pneumonia or ventilatory failure and higher viral loads. To the best of our knowledge, there is only one previous published study in patients with influenza infection that has analyzed the duration of hospitalization based on viral load \[[@CR5]\]. However, this study was developed prior to the H1N1 influenza pandemic of 2009 and none of the patients were treated with neuraminidase inhibitors.Table 4Length of hospitalization (in days) according influenza viral loadCharacteristicsAll patients (*n* = 239)Ct value (viral load)*P* value^a^*P* value^b^≤ 20 (*n* = 27)\> 20--30 (*n* = 138)\> 30 (*n* = 74)All cases7 (5--12)9 (6--13)7 (5--11)8 (5--12.25)0.190.34Pneumonia9 (5.25--14.75)13 (9--38.5)8 (4--10.75)9 (6--26)0.120.098Respiratory failure15.5 (8.5--51.5)45 (15-NA)13 (7--39.5)26 (14--53)0.4470.26Poor outcome13 (6.75--33.25)37 (12.5--53.5)8 (5--17.5)14 (11--32)0.2230.091Results are expressed as median with interquartile range (IQR). ^a^Across all Ct value groups. ^b^Between high viral load group (Ct ≤ 20) and other groups combined

Limitations {#Sec11}
-----------

A limitation of our study is that all patients included were hospitalized, which obviously correspond to greater disease severity, and it is possible that the difference in viral load is less striking in this group than if we had compared it with patients who did not require hospital admission. However, previous reports have described that there is no difference between viral loads of admitted patients compared with those in the ambulatory setting \[[@CR3]\].

Another potential limitation of the study is that the commercially available diagnostic methods for the detection of influenza virus are qualitative techniques that do not allow the performance of a viral load in a strict sense. However, the Ct value is routinely used in virology laboratories as a semi-quantitative measure of the amount of virus present in samples as has been shown in previous studies \[[@CR21]--[@CR24]\]. Our data would support the use of quantitative PCR for the management of hospitalized patients with influenza virus infection in order to discriminate the presence of abnormal findings on chest X-ray or lymphopenia. However, the currently available viral load assays present several technical problems, including the lack of an international standard, the lack of consensus on specimen types, and the influence of the timing of specimen collection in viral load results \[[@CR25]\]. In our opinion, it would be useful to have a standardized quantitative PCR as a diagnostic tool to evaluate these hospitalized patients.

In conclusion, the findings of this study suggest that in hospitalized patients with influenza virus infection (mostly A/H1N1pdm09) receiving oseltamivir therapy, a high viral load is associated with some minor radiological changes but not with a significantly worse prognosis.
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